Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
Due to a continuing shortage of generic versions of the antibiotic cefazolin by Nichi-Iko Pharmaceutical, shipments of 21 other products used as substitutes are being adjusted to supply existing customers on a priority basis. The situation was reported on April…
To read the full story
Related Article
- Nichi-Iko to Resume Normal Shipments of Cefazolin Starting October 1
September 17, 2020
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Nichi-Iko Aims to Resume Stable Supply of Cefazolin by Year-End: Exec
May 14, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
ACADEMIA
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
- Bosutinib Set to Enter PIII for ALS in Japan in 2027
October 6, 2026
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…